title: Question 1: what are the options for treating latent TB infection in children?
authors: Department of Paediatrics, The University of Melbourne, Royal Children's Hospital Melbourne, 50 Flemington Rd, Parkville, VIC 3052, Australia.
authors: Amanda
authors: A
authors: Gwee
authors: Benjamin
authors: B
authors: Coghlan
authors: Nigel
authors: N
authors: Curtis
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000009:adverse effects; D055985:Latent Tuberculosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin
keywords: General Paediatrics; Infectious Diseases; Respiratory